First Time Loading...

ESSA Pharma Inc
NASDAQ:EPIX

Watchlist Manager
ESSA Pharma Inc Logo
ESSA Pharma Inc
NASDAQ:EPIX
Watchlist
Price: 5.26 USD 0.19%
Updated: Jul 12, 2024
Have any thoughts about
ESSA Pharma Inc?
Write Note

Intrinsic Value

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. [ Read More ]

There is not enough data to reliably calculate the intrinsic value of EPIX.

Key Points:
EPIX Intrinsic Value
Base Case
Not Available
Base Case Scenario

Fundamental Analysis

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
ESSA Pharma Inc

Current Assets 137.3m
Cash & Short-Term Investments 135.9m
Receivables 215.2k
Other Current Assets 1.2m
Non-Current Assets 598.3k
PP&E 340.9k
Other Non-Current Assets 257.4k
Current Liabilities 4.2m
Accounts Payable 2m
Accrued Liabilities 2.1m
Other Current Liabilities -10
Non-Current Liabilities 253k
Other Non-Current Liabilities 253k
Efficiency

Earnings Waterfall
ESSA Pharma Inc

Revenue
0 USD
Cost of Revenue
-18.5k USD
Gross Profit
-18.5k USD
Operating Expenses
-34.1m USD
Operating Income
-34.1m USD
Other Expenses
6.4m USD
Net Income
-27.7m USD

Free Cash Flow Analysis
ESSA Pharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

EPIX Profitability Score
Profitability Due Diligence

ESSA Pharma Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

24/100
Profitability
Score

ESSA Pharma Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

EPIX Solvency Score
Solvency Due Diligence

ESSA Pharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

ESSA Pharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EPIX Price Targets Summary
ESSA Pharma Inc

Wall Street analysts forecast EPIX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EPIX is 19.38 USD with a low forecast of 15.15 USD and a high forecast of 30.45 USD.

Lowest
Price Target
15.15 USD
188% Upside
Average
Price Target
19.38 USD
268% Upside
Highest
Price Target
30.45 USD
479% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

EPIX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

EPIX Price
ESSA Pharma Inc

1M 1M
+1%
6M 6M
-47%
1Y 1Y
+75%
3Y 3Y
-82%
5Y 5Y
+127%
10Y 10Y
-94%
Annual Price Range
5.26
52w Low
2.65
52w High
10.65
Price Metrics
Average Annual Return 48.29%
Standard Deviation of Annual Returns 100.91%
Max Drawdown -96%
Shares Statistics
Market Capitalization 233.3m USD
Shares Outstanding 44 363 000
Percentage of Shares Shorted 3.31%

EPIX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

ESSA Pharma Inc Logo
ESSA Pharma Inc

Country

Canada

Industry

Biotechnology

Market Cap

233.3m USD

Dividend Yield

0%

Description

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

Contact

BRITISH COLUMBIA
Vancouver
Suite 2600, 595 Burrard Street
+17783310962.0
https://www.essapharma.com/

IPO

-

Employees

30

Officers

President, CEO & Director
Dr. David Ross Parkinson M.D.
Chief Financial Officer
Mr. David S. Wood C.M.A., CPA, CMA, CPA, M.B.A., MBA
Executive VP & COO
Mr. Peter A. Virsik M.B.A., M.S.
Chief Medical Officer & Executive VP
Dr. Alessandra Cesano M.D., Ph.D.
Executive
Nkengyal Barber

See Also

Discover More